7.SELECTION CRITERIA: All randomised or quasi-randomised clinical trials (including any relevant phase 1, 2 or 3 trials) of gene therapy for all individuals with sickle cell disease, regardless of age or setting.
DATA COLLECTION AND ANALYSIS: No trials of gene therapy for sickle cell disease were found.
MAIN RESULTS: No trials of gene therapy for sickle cell disease were reported.
AUTHORS' CONCLUSIONS: No randomised or quasi-randomised clinical trials of gene therapy for sickle cell disease were reported. Thus, no objective conclusions or recommendations in practice can be made on gene therapy for sickle cell disease. This systematic review has identified the need for well-designed, randomised controlled trials to assess the benefits and risks of gene therapy for sickle cell disease.
DATA COLLECTION AND ANALYSIS: No trials of gene therapy for sickle cell disease were found.
MAIN RESULTS: No trials of gene therapy for sickle cell disease were reported.
AUTHORS' CONCLUSIONS: No randomised or quasi-randomised clinical trials of gene therapy for sickle cell disease were reported. Thus, no objective conclusions or recommendations in practice can be made on gene therapy for sickle cell disease. This systematic review has identified the need for well-designed, randomised controlled trials to assess the benefits and risks of gene therapy for sickle cell disease.
選擇標準：所有隨機或半隨機臨床試驗(包括任何有關1，2或3試驗)基因療法所有個人鎌狀細胞疾病，不論年齡或設定。
回覆刪除數據收集和分析：沒有試驗被發現於基因治療鎌狀細胞病。
主要結果：沒有試驗被發現於基因治療鎌狀細胞疾病。
作者結論：沒有隨機或半隨機臨床試驗被發現為基因治療於鎌狀細胞疾病。因此在實驗上基因療法治療鎌狀細胞疾病，沒有客觀的結論或建議。這個系統回顧需要精心設計，隨機對照試驗以評估的好處和風險於基因療法對於鎌狀細胞疾病。